Let's Connect

News

Phase 2 Clinical Study Initiated: Evaluating NBI-‘567 for the Treatment of Adults With Alzheimer Disease

By Industry News 1 min read

​Neurocrine launches a phase 2 trial of once-daily NBI-‘567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.  — From Psychiatric Times articles Read More

Share this post
All News posts
News Industry News 9:00 am Schizophrenia: A Telltale of the Brain’s Complexity ​Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.  — From Psychiatric Times articles Read More News Industry News 9:00 am Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression ​Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.  — From Psychiatric Times articles Read More News Industry News 10:00 am Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology ​Experts discuss psychopharmacology from discovery of CYP enzymes to modern serum testing.  — From Psychiatric Times articles Read More

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Follow us

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.